322 related articles for article (PubMed ID: 24300852)
1. CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330.
Krupka C; Kufer P; Kischel R; Zugmaier G; Bögeholz J; Köhnke T; Lichtenegger FS; Schneider S; Metzeler KH; Fiegl M; Spiekermann K; Baeuerle PA; Hiddemann W; Riethmüller G; Subklewe M
Blood; 2014 Jan; 123(3):356-65. PubMed ID: 24300852
[TBL] [Abstract][Full Text] [Related]
2. Preclinical characterization of AMG 330, a CD3/CD33-bispecific T-cell-engaging antibody with potential for treatment of acute myelogenous leukemia.
Friedrich M; Henn A; Raum T; Bajtus M; Matthes K; Hendrich L; Wahl J; Hoffmann P; Kischel R; Kvesic M; Slootstra JW; Baeuerle PA; Kufer P; Rattel B
Mol Cancer Ther; 2014 Jun; 13(6):1549-57. PubMed ID: 24674885
[TBL] [Abstract][Full Text] [Related]
3. CD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cells.
Jitschin R; Saul D; Braun M; Tohumeken S; Völkl S; Kischel R; Lutteropp M; Dos Santos C; Mackensen A; Mougiakakos D
J Immunother Cancer; 2018 Nov; 6(1):116. PubMed ID: 30396365
[TBL] [Abstract][Full Text] [Related]
4. The Broad Anti-AML Activity of the CD33/CD3 BiTE Antibody Construct, AMG 330, Is Impacted by Disease Stage and Risk.
Harrington KH; Gudgeon CJ; Laszlo GS; Newhall KJ; Sinclair AM; Frankel SR; Kischel R; Chen G; Walter RB
PLoS One; 2015; 10(8):e0135945. PubMed ID: 26305211
[TBL] [Abstract][Full Text] [Related]
5. T lymphocytes can be effectively recruited for ex vivo and in vivo lysis of AML blasts by a novel CD33/CD3-bispecific BiTE antibody construct.
Aigner M; Feulner J; Schaffer S; Kischel R; Kufer P; Schneider K; Henn A; Rattel B; Friedrich M; Baeuerle PA; Mackensen A; Krause SW
Leukemia; 2013 Apr; 27(5):1107-15. PubMed ID: 23178753
[TBL] [Abstract][Full Text] [Related]
6. Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML.
Laszlo GS; Gudgeon CJ; Harrington KH; Dell'Aringa J; Newhall KJ; Means GD; Sinclair AM; Kischel R; Frankel SR; Walter RB
Blood; 2014 Jan; 123(4):554-61. PubMed ID: 24311721
[TBL] [Abstract][Full Text] [Related]
7. Characterization of CD33/CD3 Tetravalent Bispecific Tandem Diabodies (TandAbs) for the Treatment of Acute Myeloid Leukemia.
Reusch U; Harrington KH; Gudgeon CJ; Fucek I; Ellwanger K; Weichel M; Knackmuss SH; Zhukovsky EA; Fox JA; Kunkel LA; Guenot J; Walter RB
Clin Cancer Res; 2016 Dec; 22(23):5829-5838. PubMed ID: 27189165
[TBL] [Abstract][Full Text] [Related]
8. Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism.
Krupka C; Kufer P; Kischel R; Zugmaier G; Lichtenegger FS; Köhnke T; Vick B; Jeremias I; Metzeler KH; Altmann T; Schneider S; Fiegl M; Spiekermann K; Bauerle PA; Hiddemann W; Riethmüller G; Subklewe M
Leukemia; 2016 Feb; 30(2):484-91. PubMed ID: 26239198
[TBL] [Abstract][Full Text] [Related]
9. Redirection of T cells with a first fully humanized bispecific CD33-CD3 antibody efficiently eliminates AML blasts without harming hematopoietic stem cells.
Arndt C; von Bonin M; Cartellieri M; Feldmann A; Koristka S; Michalk I; Stamova S; Bornhäuser M; Schmitz M; Ehninger G; Bachmann M
Leukemia; 2013 Apr; 27(4):964-7. PubMed ID: 23325142
[No Abstract] [Full Text] [Related]
10. Bispecific antibody releasing-mesenchymal stromal cell machinery for retargeting T cells towards acute myeloid leukemia blasts.
Aliperta R; Cartellieri M; Feldmann A; Arndt C; Koristka S; Michalk I; von Bonin M; Ehninger A; Bachmann J; Ehninger G; Bornhäuser M; Bachmann MP
Blood Cancer J; 2015 Sep; 5(9):e348. PubMed ID: 26383821
[TBL] [Abstract][Full Text] [Related]
11. Clinical overview of anti-CD19 BiTE(®) and ex vivo data from anti-CD33 BiTE(®) as examples for retargeting T cells in hematologic malignancies.
Zugmaier G; Klinger M; Schmidt M; Subklewe M
Mol Immunol; 2015 Oct; 67(2 Pt A):58-66. PubMed ID: 25883042
[TBL] [Abstract][Full Text] [Related]
12. T cell engaging bispecific antibodies targeting CD33 IgV and IgC domains for the treatment of acute myeloid leukemia.
Hoseini SS; Vadlamudi M; Espinosa-Cotton M; Tran H; Feng Y; Guo HF; Xu H; Cheung I; Cheung NV
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34035113
[TBL] [Abstract][Full Text] [Related]
13. CD16xCD33 Bispecific Killer Cell Engager (BiKE) as potential immunotherapeutic in pediatric patients with AML and biphenotypic ALL.
Reusing SB; Vallera DA; Manser AR; Vatrin T; Bhatia S; Felices M; Miller JS; Uhrberg M; Babor F
Cancer Immunol Immunother; 2021 Dec; 70(12):3701-3708. PubMed ID: 34398302
[TBL] [Abstract][Full Text] [Related]
14. T-cell ligands modulate the cytolytic activity of the CD33/CD3 BiTE antibody construct, AMG 330.
Laszlo GS; Gudgeon CJ; Harrington KH; Walter RB
Blood Cancer J; 2015 Aug; 5(8):e340. PubMed ID: 26295610
[TBL] [Abstract][Full Text] [Related]
15. Fc-engineered anti-CD33 monoclonal antibody potentiates cytotoxicity of membrane-bound interleukin-21 expanded natural killer cells in acute myeloid leukemia.
Mani R; Rajgolikar G; Nunes J; Zapolnik K; Wasmuth R; Mo X; Byrd JC; Lee DA; Muthusamy N; Vasu S
Cytotherapy; 2020 Jul; 22(7):369-376. PubMed ID: 32303428
[TBL] [Abstract][Full Text] [Related]
16. Control of acute myeloid leukemia and generation of immune memory in vivo using AMV564, a bivalent bispecific CD33 x CD3 T cell engager.
Eissenberg LG; Ritchey JK; Rettig MP; Patel DA; Vij K; Gao F; Smith V; Han TH; DiPersio JF
PLoS One; 2024; 19(5):e0300174. PubMed ID: 38696390
[TBL] [Abstract][Full Text] [Related]
17. The role of CD33 as therapeutic target in acute myeloid leukemia.
Walter RB
Expert Opin Ther Targets; 2014 Jul; 18(7):715-8. PubMed ID: 24750020
[TBL] [Abstract][Full Text] [Related]
18. A novel C2 domain binding CD33xCD3 bispecific antibody with potent T-cell redirection activity against acute myeloid leukemia.
Nair-Gupta P; Diem M; Reeves D; Wang W; Schulingkamp R; Sproesser K; Mattson B; Heidrich B; Mendonça M; Joseph J; Sendecki J; Foulk B; Chu G; Fink D; Jiao Q; Wu SJ; Packman K; Elsayed Y; Attar R; Gaudet F
Blood Adv; 2020 Mar; 4(5):906-919. PubMed ID: 32150609
[TBL] [Abstract][Full Text] [Related]
19. Immunosuppressive role of CD11b
Hyun SY; Na EJ; Jang JE; Chung H; Kim SJ; Kim JS; Kong JH; Shim KY; Lee JI; Min YH; Cheong JW
Cancer Med; 2020 Oct; 9(19):7007-7017. PubMed ID: 32780544
[TBL] [Abstract][Full Text] [Related]
20. CLEC12A and CD33 coexpression as a preferential target for pediatric AML combinatorial immunotherapy.
Willier S; Rothämel P; Hastreiter M; Wilhelm J; Stenger D; Blaeschke F; Rohlfs M; Kaeuferle T; Schmid I; Albert MH; Binder V; Subklewe M; Klein C; Feuchtinger T
Blood; 2021 Feb; 137(8):1037-1049. PubMed ID: 33094319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
